Ajayi Toyin 4

What Happened

• Ajayi Toyin, a director of Evolent Health, was granted 41,096 restricted stock units (RSUs) on June 4, 2026. The filing shows an acquisition price of $0.00 (award), so no cash purchase was involved. This is a compensation award rather than a market buy or sell.

Key Details

• Transaction date: June 4, 2026 (reported on Form 4 filed June 8, 2026).
• Transaction type/code: A — Grant/Award of restricted stock units.
• Shares awarded: 41,096 RSUs; reported acquisition price: $0.00 (total reported consideration $0).
• Vesting: RSUs vest on the earlier of June 4, 2027 and the Company’s 2027 annual meeting, subject to continued service (see footnotes F1–F2).
• Shares owned after transaction: Not specified in the provided filing.
• Timeliness: Filed June 8, 2026 for a June 4 transaction — meets the standard two-business-day reporting window (not marked late).

Context

• RSUs are forward-looking awards that convert into shares if the vesting conditions are met; they are standard compensation for directors and do not represent an immediate market purchase or sale.
• Because this is a grant (not a purchase), it shouldn’t be read as a direct bullish or bearish trading signal; it reflects board compensation tied to continued service and corporate timelines.